Caracas, September 7, 2021 (PAHO / WHO)– Venezuela today received 693,600 doses of vaccines against COVID-19, as part of the first shipment made to the country by the COVAX Mechanism.
The vaccines were acquired through the Revolving Fund of the Pan American Health Organization (PAHO) —a procurement agent recognized by COVAX for the countries of the Americas region—, with the country’s own resources, and constitute the first batch of the total. of 12,068,000 doses of vaccines that Venezuela would receive through this global mechanism.
The delivery took place at dawn on Tuesday, September 7, at the Maiquetía “Simón Bolívar” International Airport, in the presence of the authorities of the Ministry of Popular Power for Health (MPPS) and PAHO. The vaccines are already in safekeeping for later distribution.
This is the first of several deliveries that will be made until the number of doses of vaccines necessary to immunize approximately 20% of the total population of the country is completed, within which are the prioritized groups following the recommendations of the Organization World Health Organization (WHO).
PAHO, Unicef and other partners have accompanied the MPPS in the technical process of planning the introduction of the COVID-19 vaccine, which included the definition of prioritized populations and vaccination strategies, and the monitoring of logistical aspects. for vaccine deployment.
Likewise, efforts have been joined for the use of Venezuelan resources abroad to guarantee the cold chain and correctly preserve the vaccines from the national and regional refrigeration warehouses to the vaccination points at the local level; as well as for the acquisition of syringes and other necessary supplies, such as kits of protective equipment for personnel participating in operational vaccination activities.
Support is also being provided in the training and mobilization of vaccinators to communities with difficult access, the strengthening of information and communication systems, the implementation of a surveillance system for post-vaccination events, and the design of monitoring plans and for the risk communication.
This first delivery consists of vaccines against COVID-19 produced by the Sinovac Biotech laboratory and included in the WHO emergency use list. This means that they have been evaluated for their quality, safety, and that the vaccines meet international standards for safety, efficacy, and manufacturing.